Cite
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
MLA
Mayer, Kenneth H., et al. “Safety, Pharmacokinetics, and Immunological Activities of Multiple Intravenous or Subcutaneous Doses of an Anti-HIV Monoclonal Antibody, VRC01, Administered to HIV-Uninfected Adults: Results of a Phase 1 Randomized Trial.” PLoS Medicine, vol. 14, no. 11, Nov. 2017, pp. 1–30. EBSCOhost, https://doi.org/10.1371/journal.pmed.1002435.
APA
Mayer, K. H., Seaton, K. E., Huang, Y., Grunenberg, N., Isaacs, A., Allen, M., Ledgerwood, J. E., Frank, I., Sobieszczyk, M. E., Baden, L. R., Rodriguez, B., Van Tieu, H., Tomaras, G. D., Deal, A., Goodman, D., Bailer, R. T., Ferrari, G., Jensen, R., Hural, J., & Graham, B. S. (2017). Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 14(11), 1–30. https://doi.org/10.1371/journal.pmed.1002435
Chicago
Mayer, Kenneth H., Kelly E. Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E. Ledgerwood, et al. 2017. “Safety, Pharmacokinetics, and Immunological Activities of Multiple Intravenous or Subcutaneous Doses of an Anti-HIV Monoclonal Antibody, VRC01, Administered to HIV-Uninfected Adults: Results of a Phase 1 Randomized Trial.” PLoS Medicine 14 (11): 1–30. doi:10.1371/journal.pmed.1002435.